20/20 is focused on the application of its proprietary technology L-IHC to develop a series of companion diagnostic products to predict the efficacy of molecularly targeted therapies in cancer.
20/20 has developed a patented platform that can be used to identify tumor biomarkers and predict patient outcome and response to therapy. Layered ImmunoHistoChemistry (L-IHC) enables multiplexing of many biomarkers in a single tissue sample while maintaining the spatial orientation of the biomarkers. It combines the visual benefits of classical pathology with the high-tech, high-throughput benefits of genomics and biochip technologies.
OPPORTUNITIES FOR COLLABORATION
Opportunities currently exist to leverage our platform with developers of cancer diagnostic and biomarkers to improve the percentage of favorable responders.
TISSUE COLLABORATORS NEEDED
In the effort to accelerate bringing L-IHC into the hands of healthcare community, we are actively inviting partners within the Oncology and Pathology communities to participate in a program to supply cancer tissue samples from patients treated with molecular targeted therapies. By participating in this program, you will help advance the field of personalized medicine into routine medical care. Using your tumor tissues supplied from a diverse spectrum of populations, we are planning to validate our L-IHC technology.